Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. 1996

B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-6057, USA.

BACKGROUND The serum histamine-releasing activity (HRA) found in a sizable percentage of patients with chronic idiopathic urticaria (CIU) has been partially characterized. However, the variable effect of individual HRA+ sera in basophils of different donors and the relationship of HRA to the clinical course require further investigation. OBJECTIVE The study was performed to characterize the HRA found in sera of some members of a sizable group of carefully evaluated patients with CIU. METHODS Sera of 70 patients with CIU, evaluated with a standard protocol, were screened for increased HRA. HRA+ sera were fractionated, heated, and tested on unaltered and altered basophils obtained from a panel of normal donors. HRA levels were compared with concomitant clinical manifestations. RESULTS HRA+ sera were found in 30% of our patients with CIU, HRA was predominantly in the IgG fraction, sensitive to 56 degrees C heating for 4 hours, and generally reacted more with IgE-stripped basophils. Considerable variation in the degree of response to HRA+ sera in the basophils of different normal subjects did not correlate with the degree of response of these cells to heterologous anti-IgE antiserum. Serum HRA levels were generally much lower when symptoms decreased in these patients with CIU. CONCLUSIONS Serum HRA from patients with CIU appears to bind most commonly to the IgE receptor and may be a marker of clinical disease activity. HRA appears in an IgG-containing fraction of the serum and may contain IgE in some cases.

UI MeSH Term Description Entries
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006636 Histamine Release The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's Fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. Histamine Liberation,Histamine Liberations,Histamine Releases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090324 Tumor Protein, Translationally-Controlled 1 A highly expressed protein in tumor cells, encoded by Tpt1 gene. It's involved in various cellular activities including protein synthesis, calcium-binding, MICROTUBULE stabilization, growth, and cell survival. Also, Tpt1 identified as a direct target gene of P53 tumor suppression. Histamine Releasing Factor,Histamine Releasing Factor, Lymphocyte-Dependent,Histamine-Releasing Factor (IgE-Dependent),Protein P23, Ehrlich Ascites Tumor,TPT1 Protein,Translationally-Controlled Tumor Protein,Factor, Histamine Releasing,Histamine Releasing Factor, Lymphocyte Dependent,Protein, TPT1,Protein, Translationally-Controlled Tumor,Translationally Controlled Tumor Protein,Tumor Protein, Translationally Controlled 1,Tumor Protein, Translationally-Controlled
D001491 Basophils Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes. Basophil
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D014581 Urticaria A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress. Hives,Urticarial Wheals,Urticarial Wheal,Urticarias,Wheal, Urticarial,Wheals, Urticarial
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
January 2001, Allergologia et immunopathologia,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
January 1996, Clinical and diagnostic laboratory immunology,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
July 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
July 1993, The Journal of allergy and clinical immunology,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
January 1991, Skin pharmacology : the official journal of the Skin Pharmacology Society,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
November 1993, The New England journal of medicine,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
July 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
March 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
December 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
B Zweiman, and M Valenzano, and P C Atkins, and T Tanus, and J A Getsy
January 2017, International archives of allergy and immunology,
Copied contents to your clipboard!